Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Israel Police arrest twenty-one as anti-war protests grow despite broad support for Iran war - 2Free Fuel Giveaway Sparks Traffic Mayhem Before Police Shut It Down
- 3Munich Security Conference chief defends inviting AfD lawmakers
- 4‘Extraordinary’ Iron Age war trumpet uncovered in England
- 5Study shows no clear link between low-fat dairy and dementia risk
- This St Nick Truly Can Advise How To Drink And Hack Your Headache
- How to watch the last supermoon of the year
- How on earth did 'Shark Tank' star Kevin O'Leary end up in 'Marty Supreme'? I'll let him explain.
- The Best Games Crossroads in History
- Al-Sharaa denies he called for 80% of Syrians to return from Germany
- Interstellar comet 3I/ATLAS will fly by Earth Friday. Here are the latest images
- Kids get diseases like lupus, too. As researchers hunt better treatments, this camp brings joy
- Doctor's orders: Eat ice cream, and other tips for a long and healthy life
- AstraZeneca to invest $2 billion as part of US manufacturing push
